Table 3.
IMP3 and p53 immunoreactivity in STIC and invasive HGSC
| |
|
Invasive HGSC of ovary |
||||
|---|---|---|---|---|---|---|
| |
STIC |
W/ STIC |
W/O STIC |
|||
| No. (%) cases | P | No. (%) cases | P | No. (%) cases | P | |
|
IMP3+ |
22 (46) |
|
20 (42) |
|
25 (40) |
|
|
IMP3- |
26 (54) |
0.82 |
28 (58) |
0.56 |
37 (60) |
0.71 |
|
p53+ |
40 (83) |
|
42 (88) |
|
53 (85) |
|
|
p53- |
8 (17) |
< 0.01 |
6 (12) |
< 0.01 |
9 (15) |
< 0.01 |
|
IMP3+/p53+ |
17 (35) |
|
17 (35) |
|
19 (31) |
|
|
IMP3+/p53- |
5 (10) |
<0.05 |
3 (6) |
<0.05 |
7 (11) |
<0.05 |
|
IMP3-/p53+ |
18 (38) |
|
20 (42) |
|
28 (45) |
|
| IMP3-/p53- | 8 (17) | 0.26 | 8 (17) | 0.16 | 9 (15) | 0.08 |
Note: The total number of patients with STIC (serous tubal intraepithelial carcinoma) cases studied was 48, while the number of invasive ovarian HGSC (high-grade serous carcinoma) without STIC was 62. The percentage of positive or negative IMP3 with the relationship to p53 staining results was calculated by the total IMP3 positive or negative cases. The p values listed in the table represented the comparisons within the same group of patients showing different status of IMP3 and/or p53.